Oragenics Inc (OGEN)
0.3089
+0.01
(+4.04%)
USD |
NYAM |
Nov 04, 16:00
0.3089
0.00 (0.00%)
After-Hours: 20:00
Oragenics Research and Development Expense (TTM): 13.38M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 13.38M |
| March 31, 2024 | 14.48M |
| December 31, 2023 | 15.49M |
| September 30, 2023 | 5.860M |
| June 30, 2023 | 7.868M |
| March 31, 2023 | 8.452M |
| December 31, 2022 | 10.07M |
| September 30, 2022 | 9.971M |
| June 30, 2022 | 10.74M |
| March 31, 2022 | 10.62M |
| December 31, 2021 | 10.59M |
| September 30, 2021 | 12.63M |
| June 30, 2021 | 12.58M |
| March 31, 2021 | 21.66M |
| December 31, 2020 | 22.11M |
| September 30, 2020 | 21.51M |
| June 30, 2020 | 21.08M |
| March 31, 2020 | 13.42M |
| December 31, 2019 | 12.12M |
| September 30, 2019 | 11.15M |
| June 30, 2019 | 9.667M |
| March 31, 2019 | 7.059M |
| December 31, 2018 | 5.972M |
| September 30, 2018 | 4.994M |
| June 30, 2018 | 4.410M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.743M |
| December 31, 2017 | 3.540M |
| September 30, 2017 | 4.500M |
| June 30, 2017 | 4.428M |
| March 31, 2017 | 4.616M |
| December 31, 2016 | 4.718M |
| September 30, 2016 | 4.283M |
| June 30, 2016 | 4.462M |
| March 31, 2016 | 9.282M |
| December 31, 2015 | 8.734M |
| September 30, 2015 | 7.941M |
| June 30, 2015 | 7.434M |
| March 31, 2015 | 2.725M |
| December 31, 2014 | 3.065M |
| September 30, 2014 | 3.586M |
| June 30, 2014 | 9.896M |
| March 31, 2014 | 9.63M |
| December 31, 2013 | 9.359M |
| September 30, 2013 | 9.020M |
| June 30, 2013 | 2.713M |
| March 31, 2013 | 8.253M |
| December 31, 2012 | 7.861M |
| September 30, 2012 | 7.973M |
| June 30, 2012 | 7.936M |
| March 31, 2012 | 2.390M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.860M
Minimum
Sep 2023
22.11M
Maximum
Dec 2020
13.40M
Average
12.58M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Shuttle Pharmaceuticals Holdings Inc | 2.805M |
| Perspective Therapeutics Inc | 28.53M |
| Alaunos Therapeutics Inc | 4.895M |
| Cocrystal Pharma Inc | 15.72M |
| Cara Therapeutics Inc | 85.14M |